Impact of high doses of 6% hydroxyethyl starch 130/0.42 and 4% gelatin on renal function in a pediatric animal model

2015 ◽  
Vol 26 (3) ◽  
pp. 259-265 ◽  
Author(s):  
Lars Witt ◽  
Silke Glage ◽  
Ralf Lichtinghagen ◽  
Lars Pape ◽  
Dietmar Boethig ◽  
...  
2014 ◽  
Vol 24 (9) ◽  
pp. 974-979 ◽  
Author(s):  
Lars Witt ◽  
Silke Glage ◽  
Katharina Schulz ◽  
Ralf Lichtinghagen ◽  
Arne Simann ◽  
...  

2013 ◽  
Vol 163 (3) ◽  
pp. S144
Author(s):  
H.A. Gürbüz ◽  
A.B. Durukan ◽  
A. Özyüksel ◽  
M. Yılmaz ◽  
R. Dogan ◽  
...  

2020 ◽  
Author(s):  
Benedict Morath ◽  
Andreas Meid ◽  
Johannes Rickmann ◽  
Jasmin Soethoff ◽  
Markus Verch ◽  
...  

Abstract Background: Fluid management is an everyday challenge in intensive care units worldwide. Data from recent trials suggest that the use of hydroxyethyl starch leads to a higher rate of acute kidney injury and mortality in septic patients. Evidence on the safety of hydroxyethyl starch used in postoperative cardiac surgery patients is lacking Methods: The aim was to determine the impact of postoperatively administered hydroxyethylstarch 130/0.42 on renal function and 90-day mortality compared to with or without balanced crystalloids in patients after elective cardiac surgery. A retrospective cohort analysis was performed including 2245 patients undergoing elective coronary artery bypass grafting or, aortic valve replacement, or a combination of both between 2015 - 2019. Acute kidney injury was defined according to the ‘kidney disease improving global outcomes’ criteria. Multivariate logistic regression yielded adjusted associations of postoperative hydroxyethyl starch administration with acute kidney injury during hospital stay and 90-day mortality. Linear mixed-effects models predicted trajectories of estimated glomerular filtration rates over the postoperative period to explore the impact of dosage and timing of hydroxyethyl starch administration.Results: A total of 1009 patients (45.0 %) suffered from acute kidney injury. Significantly less acute kidney injury of any stage occurred in patients receiving hydroxyethyl starch compared to patients receiving only crystalloids for fluid resuscitation (43.7 % vs. 51.2 % p=0.008). In multivariate analysis, the administration of hydroxyethyl starch showed a protective effect (OR 0.89 95% confidence interval (CI) (0.82-0.96)) which was less prominent in patients receiving only crystalloids (OR 0.98, 95% CI (0.95-1.00)). No association between hydroxyethyl starch and 90-day mortality (OR 1.05 95% CI (0.88-1.25)) was detected. Renal function trajectories were dose-dependent and biphasic and hydroxyethyl starch could even slow down the late postoperative decline of kidney function.Conclusion: This study showed no association between hydroxyethyl starch and the postoperative occurrence of acute kidney injury and may add evidence to the discussion about the use of hydroxyethyl starch in cardiac surgery patients. In addition, hydroxyethyl starch administered early after surgery in adequate low doses might even prevent the decline of the kidney function after cardiac surgery.


PEDIATRICS ◽  
1991 ◽  
Vol 87 (2) ◽  
pp. 148-151
Author(s):  
V. Marc Tsou ◽  
Rose M. Young ◽  
Michael H. Hart ◽  
Jon A. Vanderhoof

Aluminum toxicity is a documented cause of encephalopathy, anemia, and osteomalacia. Excretion is primarily renal; therefore, patients with renal insufficiency are at risk for aluminum accumulation and toxicity. This has been demonstrated in uremic children treated with aluminum-containing antacids. The purpose of this study was to determine whether plasma aluminum levels were elevated in infants with normal renal function during prolonged aluminum-containing antacid use. Ten study infants (mean age = 5.8 months), who had been receiving antacids for at least 1 week, were compared with 16 control infants (mean age = 9.8 months) not receiving antacids. The study patients consumed 123 ± 16 mg/kg per day (mean ± SEM) of elemental aluminum for an average of 4.7 weeks. Their plasma aluminum level (37.2 ± 7.13 µg/L) was significantly greater than that of the control group (4.13 ± 0.66 µg/L) (P < .005). It is concluded that plasma aluminum levels may become elevated in infants with normal renal function who are consuming high doses of aluminum-containing antacids. The safety of antacids containing aluminum should not be assumed and they should be used judiciously in infants, with careful monitoring of the aluminum dose and plasma level.


2015 ◽  
Vol 120 (3) ◽  
pp. 608-618 ◽  
Author(s):  
Anne Sophie Pinholt Kancir ◽  
Joergen Kühlwein Johansen ◽  
Niels Peter Ekeloef ◽  
Erling Bjerregaard Pedersen

2009 ◽  
Vol 35 (9) ◽  
pp. 1539-1547 ◽  
Author(s):  
Franziska Schabinski ◽  
Janaina Oishi ◽  
Fabio Tuche ◽  
Alain Luy ◽  
Yasser Sakr ◽  
...  

1982 ◽  
Vol 10 (3) ◽  
pp. 219
Author(s):  
Adam L. Linton ◽  
Arsenio Avila ◽  
Paul Sharkey ◽  
Andrew Petrakas ◽  
Richard J. Finley ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document